Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Monogram Orthopaedics Inc ( (MGRM) ) just unveiled an announcement.
Monogram Technologies Inc. informed its stockholders on July 30, 2025, about a new FAQ section on its Investor Relations page, addressing questions regarding its proposed acquisition by Zimmer Biomet Holdings, Inc., initially announced on July 14, 2025. This move aims to provide clarity on the transaction’s terms and timing, potentially impacting shareholder understanding and engagement with the acquisition process.
The most recent analyst rating on (MGRM) stock is a Buy with a $5.40 price target. To see the full list of analyst forecasts on Monogram Orthopaedics Inc stock, see the MGRM Stock Forecast page.
Spark’s Take on MGRM Stock
According to Spark, TipRanks’ AI Analyst, MGRM is a Neutral.
Monogram Orthopaedics Inc. shows promise due to significant technological advancements and recent regulatory clearances, which are key drivers for potential growth. However, financial instability, regulatory uncertainties, and ongoing profitability challenges weigh heavily on the overall score. The stock’s upward momentum is a positive indicator, but valuation metrics remain weak due to negative earnings and lack of dividends.
To see Spark’s full report on MGRM stock, click here.
More about Monogram Orthopaedics Inc
Average Trading Volume: 344,201
Technical Sentiment Signal: Buy
See more insights into MGRM stock on TipRanks’ Stock Analysis page.